📰 Fourth Indication News
Fourth Indication News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Fourth Indication. Real-time updates on events, politics, business and more.
September 7, 2022
KITE’S  CAR  T-CELL  THERAPY  TECARTUS®  (BREXUCABTAGENE  AUTOLEUCEL)  GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF  RELAPSED  OR  REFRACTORY  ACUTE  LYMPHOBLASTIC  LEUKAEMIA  (r/r ALL) -- Approval Marks Kite’...
September 6, 2022
-- Approval Marks Kite's Fourth Indication in Europe for its Two Cell Therapies and First in Leukemia -- -- Overall Complete Remission of 71% and a Median Overall Survival of More Than Two Years
October 2, 2021
65% of Patients Achieved Overall Complete Remission with Tecartus -- -- High Unmet Need: Fifty Percent of Adult Patients Will Relapse on Currently Available Treatments -- -- Approval Marks Kite’s Fourth Indication for its Cell Therapies and First in Leukemia -- Kite, a Gilead Company today announced the U.S. Food and Drug Administration has granted approval for Tecartus ® for the treatment of adult patients with ...